Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Closes Acquisition of Merck's RNAi Assets


Alnylam Pharmaceuticals this week announced that it has closed its previously announced acquisition of Merck's RNAi assets, including its Sirna Therapeutics subsidiary.

Merck, which acquired Sirna in 2007 for $1.1 billion, unveiled a company-wide restructuring last year that included a reduction in emphasis on platform technologies, including RNAi. In January, the company disclosed that it would sell its RNAi assets to Alnylam in exchange for $25 million in cash and $150 million in stock.